ArticleTechnology in cancer research & treatment

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.

Shu Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.